Sign Out
Non-Small Cell Lung Cancer (NSCLC): Gavreto is indicated for the treatment of adult patients with rearranged during transfection (RET) fusion-positive, advanced or metastatic NSCLC.
RET-Mutant Medullary Thyroid Cancer (MTC): Gavreto is indicated for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant MTC who require systemic therapy.
RET-Fusion Positive Thyroid Cancer: Gavreto is indicated for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET-fusion positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate).
